drugset / Trial / NCT06648031
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in combination, in overweight or obese, pre- and type 2 diabetic participants.
Timeline
- Start
- 2024-12-04
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBD | Unknown | 250 mg | Oral |
| Subject | Semaglutide | Peptide | 3.5 mg | Oral |
| Subject | Semaglutide | Peptide | 7 mg | Oral |
| Subject | Tirzepatide | Peptide | 40 mg | — |